黑色素瘤中抗细胞毒性T淋巴细胞抗原4（CTLA-4）治疗的标志物。

Markers for anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) therapy in melanoma.

作者信息

Postow Michael A, Yuan Jianda, Kitano Shigehisa, Lesokhin Alexander M, Wolchok Jedd D

机构信息

Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

出版信息

Methods Mol Biol. 2014;1102:83-95. doi: 10.1007/978-1-62703-727-3_6.

DOI:10.1007/978-1-62703-727-3_6

PMID:24258975

Abstract

Therapeutic strategies that block Cytotoxic T lymphocyte antigen-4 (CTLA-4) enhance antitumor immunity and prolong the lives of patients with metastatic melanoma. However, only a subset of patients benefit, and responses are often delayed due to heterogeneous response kinetics. Ongoing monitoring of the immunologic effects of therapy and correlating these immunologic changes with patient outcomes continue to be important goals to better identify possible mechanisms of clinical activity of these agents. This chapter introduces the major areas of investigation in monitoring patients treated with CTLA-4 blockade and provides specific details of our experience performing selected assays.

摘要

阻断细胞毒性T淋巴细胞抗原4（CTLA-4）的治疗策略可增强抗肿瘤免疫力，并延长转移性黑色素瘤患者的生命。然而，只有一部分患者能从中受益，而且由于反应动力学的异质性，反应往往会延迟。持续监测治疗的免疫效果，并将这些免疫变化与患者的预后相关联，仍然是更好地确定这些药物临床活性可能机制的重要目标。本章介绍了监测接受CTLA-4阻断治疗患者的主要研究领域，并提供了我们进行特定检测的经验细节。